How do I know? Because the senior opthamologist I worked with knows my interest and discussed it with Novartis reps. Novartis was hoping to go with their own Beovue, but after they admitted the problems with inflammation one of their future multibillion dollar treatments evaporated. Novartis was shocked by that. But they've been following Opt302's progress and I bet they're not the only ones now patents have expired.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-45
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.005(1.39%) |
Mkt cap ! $398.3M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 34.5¢ | $755.3K | 2.117M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27776 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13607 | 7 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |